Preclinical Efficacy Data of Sangamo’s ZFN Based Human Stem Cell Therapy for HIV Published

Published July 6, 2010

Preclinical efficacy data of Sangamo’s ZFN based human stem cell therapy for HIV published
Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.
Read more on News-Medical-Net